Titre:
  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Auteur:Benboubker, Lotfi; Dimopoulos, Meletios Athanassios; Dispenzieri, Angela; Catalano, John; Belch, Andrew AR; Cavo, Michele; Pinto, Antonello; Weisel, Katja; Ludwig, Heinz; Bahlis, Nizar NJ; Banos, Anne; Tiab, Mourad; Delforge, Michel; Cavenagh, Jamie; Geraldes, Catarina; Lee, Je-Jung; Chen, Christine; Oriol, Albert; de la Rubia, Javier; Qiu, Lugui; White, Darrell J; Binder, Daniel; Anderson, Kenneth Carl; Fermand, Jean-Paul; Moreau, Philippe; Attal, Michel; Knight, Robert; Chen, Guang; Van Oostendorp, Jason; Jacques, Christian; Ervin-Haynes, Annette; Avet-Loiseau, Herve; Hulin, Cyrille; Facon, Thierry; Meuleman, Nathalie; et al.
Informations sur la publication:The New England journal of medicine, 371, 10, page (906-917)
Statut de publication:Publié, 2014-09
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Dexamethasone -- administration & dosage -- adverse effects
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Melphalan -- administration & dosage
Middle Aged
Multiple Myeloma -- drug therapy -- immunology
Prednisone -- administration & dosage
Thalidomide -- administration & dosage -- adverse effects -- analogs & derivatives
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa1402551
info:pmid/25184863